Abstract library

25 results for "Mineur".
#1387 FOLFOX in Neuroendocrine Tumors
Introduction: Favorable toxicity profile and significant antitumor activity of FU-oxaliplatin in several malignancies led us to evaluate FOLFOX in advanced neuroendocrine carcinomas (NETs).
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Marjorie Faure
Authors: Faure M, Raoul J L, Autret A, Mineur L, ...
#2118 Reassessment of Risk Factors Associated with Locoregional Lymph Nodal Metastases in Well-Differentiated Appendiceal Neuroendocrine Neoplasms
Introduction: To prevent loco-regional recurrence and subsequent development of distant metastases in Appendiceal Neuro-Endocrine Neoplasms (ANEN), the existing Guidelines have identified risk factors which would indicate a prophylactic right hemicolectomy(RHC).
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr. Michail Galanopoulos
#2961 Our Experience Using a New Scoring System to Detect Disease Recurrence after Curative Surgical Resection of Well-Differentiated Pancreatic Neuroendocrine Tumors
Introduction: For patients with nonfunctioning pNET  ≥20 mm in size without distant metastasis, complete surgical resection is recommended as the primary curative strategy. Effective follow‐up programs are designed to detect recurrence at an early stage, given that treatment of limited disease has the most favorable outcome. However, data on post‐curative surgical recurrence remains limited, making it challenging to determine the best follow‐up strategy and to detect the best treatment options as an adjuvant therapy for selected patients.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Laura Mastrangelo
#3009 OPERA: Observational Study of Perception of Information and Quality of Life in Patients with Gastroenteropancreatic NeuroEndocrine TumoRs Starting LAnreotide Autogel–Baseline Characteristics
Introduction: Information provided to patients (pts) with neuroendocrine tumors (NETs) about burden and treatment proposed may influence pts’ adherence to treatment, outpatient monitoring and quality of life (QoL), but can also cause anxiety.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: PhD Delphine Gueguen
#106 Gastroenteropancreatic neuroendocrine tumors: single institution clinicopathological study
Introduction: Neuroendocrine cells are widely distributed throughout the body, and neoplasms from these dispersed cells can arise at many sites. They are distinguished into two broad categories: 1) Tumors identified as small cell lung carcinomas with biology and natural history of a high-grade malignancy and characteristics of small cell undifferentiated or anaplastic appearance by light microscopy. The WHO categorizes these tumors as poorly-differentiated neuroendocrine carcinomas; 2) Well-defined neuroendocrine tumors (NETs) with variable, but most lyindolent biologic behavior and characteristic well-differentiated histologic features. The majority arise in the gastrointestinal tract and collectively they are referred as gastroenteropancreatic neuroendocrine tumors (GEP/NETs). They include carcinoid tumors, pancreatic islet cell tumors (gastrinoma, insulinoma, glucagonoma, VIPoma, somatostatinoma), paragangliomas, pheochromocytomas, and medullary thyroid carcinomas. The WHO classifies the GEP/NETs as well-differentiated NETs (carcinoid tumors) if they are noninvasive and have benign behavior or uncertain malignant potential. In contrast, GEP/NETs with characteristics of low-grade malignancy with invasion of the muscularis propria or beyond, or metastases, are characterized as well-differentiated neuroendocrine carcinomas (malignant carcinoids). Pancreatic islet cell tumors, whether functioning or not, are classified as well-differentiated NETs or well-differentiated neuroendocrine carcinomas, due to the (depending on) histologic characteristics. The WHO classification for gastroenteropancreatic NETs based on stage (ie size and presence of metastases) and grade (mitotic rate, perineural and lymphovascular invasion, Ki-67 proliferative index) categorizes them as well-differentiated NETs, e.g., carcinoid tumors, or as well-differentiated neuroendocrine carcinomas.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Michael M. Vaslamatzis
#506 Paraneoplastic Neurological Syndrome in a Patient with a Pancreatic Well-Differentiated Endocrine Tumor
Introduction: Few studies report the association of neurological syndromes with a carcinoid, the majority being small-cell lung cancer.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD, PhD Maria Pia Brizzi
#782 Appendix Well-Differentiated Neuroendocrine Tumors (A-WDNETs) at a Large Tertiary Center: Clinical-Pathological Features and Long-Term Follow-Up Evaluation
Introduction: A-WDNETs comprise 32-57% of appendix tumors, diagnosed incidentally in 0.3-0.9% appendectomies (AP). Overall survival is good, but malignant behavior remains controversial.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr. John Preto
#1004 Prognostic Value of Histophathological Features of Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (NETs) are rare neoplasms. NETs are clinically diverse and can be divided into functioning and non-functioning tumors.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: MD Ernesto Jesus Barzola Navarro
#1015 Pancreatic Neuroendocrine Tumors: Experience in a Spanish Reference Center
Introduction: Pancreatic neuroendocrine tumors (pNET) derived from the hormone-producing cells in the pancreas whose actual prevalence, natural history and optimal treatment raises controversy.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Cristina Tejera
#1050 Recurrent Disease After Curative Pancreatic Resection for Patients with Non-Functional Neuroendocrine Tumor; Identify the High Risk Patient
Introduction: Since the overall favourable survival, detection of recurrent disease is one of the main goals during follow up in patients with resected pancreatic neuroendocrine tumors (pNET).
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Anneke Jilesen
Keywords: NF